Identification
- Summary
Dequalinium is a quaternary ammonium cation antimicrobial agent used to treat common infections of the mouth and throat, as well as vaginal candidiasis.
- Generic Name
- Dequalinium
- DrugBank Accession Number
- DB04209
- Background
Dequalinium is an antibacterial agent. It is a amphipathic cation with two aminoquinaldinium rings at both ends. First used as an antiseptic and disinfectant in the 1950s, dequalinium can still be found in different OTC products to treat conditions of oral infections and inflammation.11 It is also used to treat bacterial vaginosis as vaginal tablets.13
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Dequalinium (DB04209)
- Weight
- Average: 456.6654
Monoisotopic: 456.3252973 - Chemical Formula
- C30H40N4
- Synonyms
- 1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride
- 1,1'-Decamethylenebis(4-aminoquinaldinium chloride)
- Decamethylenebis(4-aminoquinaldinium chloride)
- External IDs
- LSM-5846
Pharmacology
- Indication
Dequalinium is used in several OTC products to treat mouth infections and inflammation, such as tonsillitis, pharyngitis, and gingivitis.11 As vaginal tablets, dequalinium is indicated for the treatment of bacterial vaginosis in adult women under 55 years of age.13
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Dequalinium is an antimicrobial against Gram negative and positive bacteria, yeast and protozoa. It primarily mediates this action by increasing the cell permeability with subsequent loss of enzyme activity under a rapid bactericidal and fungicidal action. The enzymatic inactivation initially might be reversible but becomes irreversible after a longer contact time between the drug and bacteria 1. The bactericidal and fungicidal effect of dequalinium chloride has been demonstrated to occur within 30–60 min 7. Dequalinium targets a broad spectrum of microorganisms including aerobic and anaerobic bacteria, as well as Candida species.
- Mechanism of action
Dequalinium has a multiple mode of action. It disrupts the cell permeability of the bacteria by absorbing onto the bacterial cell surface and diffusing across the membrane. It also binds to the cytoplasmic membrane with subsequent formation of complexes and protein precipitation and lyses the membrane in adequate concentrations, perturbing osmotic exchange. Loss of normal enzymatic activity is achieved through several different processes. Denaturation of proteins results in inhibition of bacterial cell metabolism. Disruption of bacterial energy production is mediated through inhibition of glucose metabolism and inhibition of mitochondrial ATP synthesis via inhibition of bacterial F1-ATPase. Protein synthesis is also terminated at the level of ribosomes. Bacterial nucleic acids are also affected through direct binding of the drug to DNA in vitro, and precipitation of cytoplasmic material with nucleic acids being the most sensitive 1. The cationic form of dequalinium accumulates in the mitochondria and promotes anticancer activity in human leukemia cells. It mediates a cytotoxic effect by altering redox balance in cells and downregulating Raf/MEK/ERK1/2 and PI3K/Akt signaling pathways in these cells which leads to cell death by apoptosis and/or necrosis 3,4,5. Dequalinium inhibits mycothiol ligase activity in Mycobacterium tuberculosis strains 9.
Target Actions Organism AE3 ubiquitin-protein ligase XIAP antagonistinhibitorHumans UcGMP-gated cation channel alpha-1 blockerHumans UCalcium-activated potassium channel subunit alpha-1 inhibitorHumans UHTH-type transcriptional regulator QacR Not Available Staphylococcus aureus UAcriflavine resistance protein B Not Available Escherichia coli (strain K12) - Absorption
The degree of absorption is minimal in case of topical or vaginal administration thus systemic exposure is negligible. <0.1 % is absorbed systemically after oral administration.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral LD50 value of dequalinium chloride for mouse is 300mg/kg. Lethal dose (LD50) of a single intraperitoneal administration in a murine model system is 18.3 mg/kg. The majority of the adverse reactions of vaginal dequalinium tablets in clinical studies (about 90 %) were local reactions, particularly vaginal discharge, vulvovaginal pruritus, and a vaginal burning sensation. Dequalinuim is not reported to possess embryo-foetal toxicity at clinically relevant doses.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Dequalinium is combined with Acenocoumarol. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dequalinium. Dicoumarol The risk or severity of bleeding can be increased when Dequalinium is combined with Dicoumarol. Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Dequalinium. Fluindione The risk or severity of bleeding can be increased when Dequalinium is combined with Fluindione. Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Dequalinium. Phenindione The risk or severity of bleeding can be increased when Dequalinium is combined with Phenindione. Phenprocoumon The risk or severity of bleeding can be increased when Dequalinium is combined with Phenprocoumon. Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dequalinium. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dequalinium. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Dequalinium acetate P8W4UX112S 4028-98-2 IWYNVAJACBPVLT-UHFFFAOYSA-N Dequalinium bromide Not Available Not Available Not applicable Dequalinium chloride XYS8INN1I6 522-51-0 LTNZEXKYNRNOGT-UHFFFAOYSA-N Dequalinium iodide Not Available Not Available Not applicable Dequalinium undecenoate Not Available Not Available Not applicable - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Vablys Tablet 10 mg Vaginal Duchesnay Inc. 2022-05-17 Not applicable Canada 
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image AXCEL DEXXON LOZENGES Lozenge Oral KOTRA PHARMA (M) SDN. BHD. 2020-09-08 Not applicable Malaysia 
Citrex DQM Lozenges Lemon Ginger 0.25mg Lozenge 0.25 mg Oral IDAMAN PHARMA MANUFACTURING SDN BHD 2020-09-08 2021-12-12 Malaysia Citrex DQM Lozenges Lemon Honey 0.25mg Lozenge Oral IDAMAN PHARMA MANUFACTURING SDN BHD 2020-09-08 Not applicable Malaysia Citrex DQM Lozenges Orange 0.25mg Lozenge Oral IDAMAN PHARMA MANUFACTURING SDN BHD 2020-09-08 Not applicable Malaysia DELIN Lozenge 0.25 mg Oral บริษัท โรงงานเภสัชกรรมแอตแลนติค จำกัด 2020-06-22 Not applicable Thailand 
Dequa 250 mcg Lozenges Lozenge Oral DYNAPHARM (M) SDN BHD 2020-09-08 Not applicable Malaysia Dequadin Lozenge 0.25 mg Oral Boyd Pharmaceuticals Inc. 1997-04-01 Not applicable Canada DEQUADIN LEMON Lozenge Oral STERLING DRUG (MALAYA) SDN. BHD. 2020-09-08 Not applicable Malaysia DEQUADIN LOZENGE (ORIGINAL) Lozenge Oral STERLING DRUG (MALAYA) SDN. BHD. 2020-09-08 Not applicable Malaysia DEQUADIN LOZENGE LEMON Lozenge Oral STERLING DRUG (MALAYA) SDN. BHD. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DECATYLEN LOZENGE Dequalinium chloride (0.25 mg) + Cinchocaine hydrochloride (0.03 mg) Lozenge Oral APEX PHARMA MARKETING PTE. LTD. 1990-06-25 Not applicable Singapore DEQ LOZENGE Dequalinium chloride (0.25 mg) + Tyrothricin (1 mg) Tablet Oral ATLANTIC PHARMACEUTICAL (S) PTE LTD 1990-01-13 Not applicable Singapore JASIMENTH C PASTILLES Dequalinium chloride (0.45 mg) + Anise oil (0.7 mg) + Ascorbic acid (20 mg) + Levomenthol (1 mg) Pastille Oral PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia ดีโตร Dequalinium (0.25 MG) + Benzocaine (5 MG) Lozenge Oral บริษัท เอเชี่ยนยูเนี่ยนแล็บบอราตอรี่ จำกัด จำกัด 1987-07-13 Not applicable Thailand ยาอมดีโทซ Dequalinium (0.25 MG) + Ascorbic acid (50 MG) Lozenge Oral บริษัท ไทย พี ดี เคมีคอล จำกัด จำกัด 1985-06-29 Not applicable Thailand
Categories
- ATC Codes
- D08AH01 — Dequalinium
- D08AH — Quinoline derivatives
- D08A — ANTISEPTICS AND DISINFECTANTS
- D08 — ANTISEPTICS AND DISINFECTANTS
- D — DERMATOLOGICALS
- Drug Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Local
- Antiseptics and Disinfectants
- Dermatologicals
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Heterocyclic Compounds, Fused-Ring
- Miscellaneous Anti-infectives
- Quinoline Derivatives
- Quinolines
- Quinolinium Compounds
- Throat Preparations
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Aminoquinolines and derivatives
- Direct Parent
- 4-aminoquinolines
- Alternative Parents
- Methylpyridines / Aminopyridines and derivatives / Pyridinium derivatives / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Hydrocarbon derivatives / Organic cations
- Substituents
- 4-aminoquinoline / Amine / Aminopyridine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Methylpyridine / Organic cation
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- quinolinium ion (CHEBI:41872)
- Affected organisms
- Candida albicans and other yeasts
- Trichomonas vaginalis, Giardia duodenalis, and Entamoeba histolytica
- Bacteria and protozoa
- Bacteroides
- Peptostreptococcus
Chemical Identifiers
- UNII
- E7QC7V26B8
- CAS number
- 6707-58-0
- InChI Key
- PCSWXVJAIHCTMO-UHFFFAOYSA-P
- InChI
- InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2
- IUPAC Name
- 4-amino-1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium
- SMILES
- CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2
References
- General References
- Mendling W, Weissenbacher ER, Gerber S, Prasauskas V, Grob P: Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet. 2016 Mar;293(3):469-84. doi: 10.1007/s00404-015-3914-8. Epub 2015 Oct 27. [Article]
- Timaner M, Bril R, Kaidar-Person O, Rachman-Tzemah C, Alishekevitz D, Kotsofruk R, Miller V, Nevelsky A, Daniel S, Raviv Z, Rotenberg SA, Shaked Y: Dequalinium blocks macrophage-induced metastasis following local radiation. Oncotarget. 2015 Sep 29;6(29):27537-54. doi: 10.18632/oncotarget.4826. [Article]
- Sancho P, Galeano E, Estan MC, Ganan-Gomez I, Boyano-Adanez Mdel C, Garcia-Perez AI: Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Exp Biol Med (Maywood). 2012 Aug;237(8):933-42. doi: 10.1258/ebm.2012.011423. Epub 2012 Aug 8. [Article]
- Garcia-Perez AI, Galeano E, Nieto E, Sancho P: Dequalinium induces human leukemia cell death by affecting the redox balance. Leuk Res. 2011 Oct;35(10):1395-401. doi: 10.1016/j.leukres.2011.03.012. Epub 2011 Apr 8. [Article]
- Garcia-Perez AI, Galeano E, Nieto E, Estan MC, Sancho P: Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Leuk Res. 2014 Jul;38(7):795-803. doi: 10.1016/j.leukres.2014.01.009. Epub 2014 Jan 28. [Article]
- Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G: Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittelforschung. 2002;52(9):699-705. [Article]
- D'Auria FD, Simonetti G, Strippoli V: [Antimicrobial characteristics of a tincture of dequalinium chloride]. Ann Ig. 1989 Sep-Oct;1(5):1227-41. [Article]
- Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr, Chen LB: Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5444-8. [Article]
- Gutierrez-Lugo MT, Baker H, Shiloach J, Boshoff H, Bewley CA: Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. J Biomol Screen. 2009 Jul;14(6):643-52. doi: 10.1177/1087057109335743. Epub 2009 Jun 12. [Article]
- Gamboa-Vujicic G, Emma DA, Liao SY, Fuchtner C, Manetta A: Toxicity of the mitochondrial poison dequalinium chloride in a murine model system. J Pharm Sci. 1993 Mar;82(3):231-5. [Article]
- Bailly C: Medicinal applications and molecular targets of dequalinium chloride. Biochem Pharmacol. 2021 Apr;186:114467. doi: 10.1016/j.bcp.2021.114467. Epub 2021 Feb 10. [Article]
- Laboratorios Neo: Bucoseptol (benzocaine/dequalinium chloride) for oral use [Link]
- Health Canada Approved Drug Products: VABLYS (Dequalinium) Vaginal Tablets [Link]
- External Links
- PubChem Compound
- 2993
- PubChem Substance
- 46507206
- ChemSpider
- 2886
- BindingDB
- 50048403
- 3226
- ChEBI
- 41872
- ChEMBL
- CHEMBL333826
- ZINC
- ZINC000001655706
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- DEQ
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Dequalinium
- PDB Entries
- 1jt6 / 1oyd / 3arp / 3art / 3br1 / 3br2 / 3bt9 / 3btj / 3vw0
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Vulvovaginal Candidiasis 1 3 Completed Treatment Bacterial Vaginosis (BV) 1 Not Available Completed Not Available Bacterial Vaginoses 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Lozenge Oral Tablet Oral Lozenge Oral 0.25 mg Lozenge Oral Tablet Oral 0.25 mg Solution Oral Spray Oral Lozenge Oral .25 mg / loz Solution Buccal 0.5 % w/v Liquid Oral 0.5 % Solution Oral Insert Vaginal Solution Topical Ointment Topical Tablet Vaginal 10 mg Tablet Vaginal Pastille Oral Pastille Oral Solution Oral 1 mg/10ml Lozenge Oral 0.25 mg - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US4946849 No 1990-08-07 2002-10-01 US 
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) Decomposes at 326ºC MSDS - Predicted Properties
Property Value Source Water Solubility 4.77e-07 mg/mL ALOGPS logP 0.16 ALOGPS logP -3.6 ChemAxon logS -9 ALOGPS pKa (Strongest Basic) -0.34 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 59.8 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 147 m3·mol-1 ChemAxon Polarizability 56.76 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5208 Blood Brain Barrier + 0.924 Caco-2 permeable + 0.5756 P-glycoprotein substrate Substrate 0.6725 P-glycoprotein inhibitor I Non-inhibitor 0.7203 P-glycoprotein inhibitor II Inhibitor 0.7281 Renal organic cation transporter Inhibitor 0.6769 CYP450 2C9 substrate Non-substrate 0.8745 CYP450 2D6 substrate Non-substrate 0.5072 CYP450 3A4 substrate Non-substrate 0.5434 CYP450 1A2 substrate Non-inhibitor 0.6703 CYP450 2C9 inhibitor Non-inhibitor 0.9119 CYP450 2D6 inhibitor Inhibitor 0.8931 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Inhibitor 0.6677 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5512 Ames test AMES toxic 0.5875 Carcinogenicity Non-carcinogens 0.9063 Biodegradation Not ready biodegradable 0.9969 Rat acute toxicity 2.6736 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.823 hERG inhibition (predictor II) Inhibitor 0.9123
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- AntagonistInhibitor
- General Function
- Zinc ion binding
- Specific Function
- Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation,...
- Gene Name
- XIAP
- Uniprot ID
- P98170
- Uniprot Name
- E3 ubiquitin-protein ligase XIAP
- Molecular Weight
- 56684.41 Da
References
- Orzaez M, Gortat A, Sancho M, Carbajo RJ, Pineda-Lucena A, Palacios-Rodriguez Y, Perez-Paya E: Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain. Apoptosis. 2011 May;16(5):460-7. doi: 10.1007/s10495-011-0582-4. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Blocker
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Visual signal transduction is mediated by a G-protein coupled cascade using cGMP as second messenger. This protein can be activated by cyclic GMP which leads to an opening of the cation channel and...
- Gene Name
- CNGA1
- Uniprot ID
- P29973
- Uniprot Name
- cGMP-gated cation channel alpha-1
- Molecular Weight
- 79584.825 Da
References
- Rosenbaum T, Islas LD, Carlson AE, Gordon SE: Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
- Gene Name
- KCNMA1
- Uniprot ID
- Q12791
- Uniprot Name
- Calcium-activated potassium channel subunit alpha-1
- Molecular Weight
- 137558.115 Da
References
- Castle NA, Haylett DG, Morgan JM, Jenkinson DH: Dequalinium: a potent inhibitor of apamin-sensitive K+ channels in hepatocytes and of nicotinic responses in skeletal muscle. Eur J Pharmacol. 1993 May 19;236(2):201-7. [Article]
- Kind
- Protein
- Organism
- Staphylococcus aureus
- Pharmacological action
- Unknown
- General Function
- Transcriptional repressor of qacA. Binds to IR1, an unusually long 28 bp operator, which is located downstream from the qacA promoter and overlaps its transcription start site. QacR is induced from its IR1 site by binding to one of many structurally dissimilar cationic lipophilic compounds, which are also substrates of QacA.
- Specific Function
- Dna binding
- Gene Name
- qacR
- Uniprot ID
- P0A0N4
- Uniprot Name
- HTH-type transcriptional regulator QacR
- Molecular Weight
- 22174.175 Da
References
- Peters KM, Schuman JT, Skurray RA, Brown MH, Brennan RG, Schumacher MA: QacR-cation recognition is mediated by a redundancy of residues capable of charge neutralization. Biochemistry. 2008 Aug 5;47(31):8122-9. doi: 10.1021/bi8008246. Epub 2008 Jul 11. [Article]
- Murray DS, Schumacher MA, Brennan RG: Crystal structures of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization. J Biol Chem. 2004 Apr 2;279(14):14365-71. doi: 10.1074/jbc.M313870200. Epub 2004 Jan 15. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Identical protein binding
- Specific Function
- AcrA-AcrB-AcrZ-TolC is a drug efflux protein complex with broad substrate specificity that uses the proton motive force to export substrates.Involved in contact-dependent growth inhibition (CDI), a...
- Gene Name
- acrB
- Uniprot ID
- P31224
- Uniprot Name
- Multidrug efflux pump subunit AcrB
- Molecular Weight
- 113572.75 Da
References
- Yu EW, Aires JR, McDermott G, Nikaido H: A periplasmic drug-binding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J Bacteriol. 2005 Oct;187(19):6804-15. doi: 10.1128/JB.187.19.6804-6815.2005. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 24, 2022 08:21